Real World Experience
with EYLEA® (aflibercept) 8 mg
EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).
Explore the real-world experiences of UK clinicians implementing EYLEA® (aflibercept) 8 mg, highlighting its potential to address unmet needs in the treatment of nAMD, DMO and RVO.
Confidence in Every Dose
Webinar 2: Real-World Outcomes with EYLEA 8 mg
Explore our second 'Confidence in Every Dose' webinar through bite-sized videos where UK speakers share their insights on audits and patient datasets related to EYLEA 8 mg.
RVO 12-month Audit: Aalborg University Hospitals, Denmark
In this video, Lasse Cehofski presents 12-month audit results using EYLEA 8 mg for patients with RVO.
- Duration: ~8 minutes
- 68 treatment-naïve & 156 treatment-experienced eyes
- RVO
Prescribing information for EYLEA® (aflibercept) can be found here.
Latest EYLEA 8 mg Audits from the UK and Scotland
These UK audit videos highlight the real life usage of EYLEA 8 mg within leading ophthalmology clinics. Watch these videos to learn more about the impact of EYLEA 8 mg on patient care and clinical practice.
Promotional Meeting: Real World Impact and Community Stories from West of Scotland
In this meeting recording, clinicians from Scotland, Peter Cackett, Alasdair Purdie, Ehab Abdelkader, and Sidharth Kaushal, share their experiences of using EYLEA 8 mg in local practice, highlighting the importance of increasing clinical capacity through durable treatment options.
- Duration: ~24 minutes
- nAMD & DMO
Prescribing information for EYLEA® (aflibercept) can be found here.
Confidence in Every Dose
Webinar 1: Real-World Outcomes with EYLEA 8 mg
Explore our 'Confidence in Every Dose' webinar through bite-sized videos where UK speakers share their insights on audits and patient datasets related to EYLEA 8 mg.
The Royal Wolverhampton NHS Trust and NHS Greater Glasgow and Clyde
In this video, Niro Narendran presents EYLEA 8 mg audit results from the Royal Wolverhampton NHS Trust and NHS Greater Glasgow and Clyde. The Royal Wolverhampton NHS Trust: An audit of 20 treatment-experienced eyes that were switched to EYLEA 8 mg. Prior to the switch, these patients had undergone extensive therapy, averaging 40 previous anti-VEGF injections each. NHS Greater Glasgow and Clyde: An audit of 39 treatment-experienced eyes that were switched to EYLEA 8 mg.
- Duration: ~4 minutes
- Treatment-experienced patients
- nAMD
Prescribing information for EYLEA® (aflibercept) can be found here.
International Medical Retina Congress Highlights on EYLEA 8 mg
These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg and highlight key learnings and updates from recent congresses.
Connect with us! If you find these videos helpful, we invite you to stay updated on the latest resources regarding EYLEA 8 mg, including highlights from international congresses. Click below to reach out to us or to register for our communications!
American Academy of Ophthalmology (AAO) Congress | October 2025
In this 5-minute video, Helen Devonport (Consultant Ophthalmologist, Bradford Teaching Hospitals NHS Foundation Trust) presents the real-world use of EYLEA 8 mg for treatment-naïve and treatment experienced patients with nAMD and DMO from the IRIS Registry.
Prescribing information for EYLEA® (aflibercept) can be found here.
Abbreviations
DMO, diabetic macular oedema. HCP, healthcare professional. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service. RVO, retinal vein occlusion. RWE, real-world evidence. SmPC, Summary of Product Characteristics. UK, United Kingdom. VEGF, vascular endothelial growth factor.
Prescribing information for EYLEA® (aflibercept) can be found here.
PP-EYL-GB-3185 | June 2026